Edition:
India

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,769.50GBp
12 Dec 2017
Change (% chg)

54.50 (+1.47%)
Prev Close
3,715.00
Open
3,700.00
Day's High
3,770.50
Day's Low
3,696.50
Volume
504,018
Avg. Vol
2,798,653
52-wk High
5,067.00
52-wk Low
3,435.50

Select another date:

Fri, Dec 8 2017

BRIEF-Shire Plc Appoints ‍John Miller As Interim CFO

* SHIRE PLC SAYS ‍JOHN MILLER TO SERVE AS INTERIM CFO WITH EFFECT FROM JAN 1, 2018 UNTIL THOMAS DITTRICH COMMENCES HIS EMPLOYMENT WITH CO - SEC FILING​

Shire in deal to develop a new way to administer hemophilia drug

Shire Plc said on Tuesday it had partnered with a California-based company to develop a new way to administer a drug to treat hemophilia A.

Shire in deal to develop a new way to administer hemophilia drug

Dec 5 Shire Plc said on Tuesday it had partnered with a California-based company to develop a new way to administer a drug to treat hemophilia A.

BRIEF-Shire And Rani Therapeutics enter into collaboration to evaluate use of the Rani Pill technology

* SHIRE AND RANI THERAPEUTICS ENTER INTO COLLABORATION TO EVALUATE USE OF THE RANI PILL(TM) TECHNOLOGY FOR THE ORAL DELIVERY OF FACTOR THERAPY

UPDATE 4-Roche haemophilia drug wins FDA nod, with a warning

* Shares in rival Shire climb 6 pct (Adds projected price of drug, company comment)

BRIEF-Omega Advisors dissolves share stake in Carrizo Oil & Gas, ups in Shire PLC

* Omega Advisors Inc dissolves share stake in Carrizo Oil & Gas Inc - SEC Filing‍​

BRIEF-Third Point takes share stake in Macerich, dissolves share stake in Humana

* Third Point LLC dissolves Class A share stake in Charter Communications Inc - SEC filing

BRIEF-Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc

* Xenetic Biosciences enters into sublicense agreement related to its Polyxen technology with Baxalta Inc., a wholly-owned subsidiary of Shire Plc

Shire to make genetic disease drug itself to secure supply

LONDON Shire will start making a genetic disease medicine itself after it was hit by supply problems, the London-listed firm said on Friday as it reported a sharp rise in profit.

UPDATE 1-Shire to make genetic disease drug itself to secure supply

* Shares up 1.2 pct (Adds CEO comments, analyst reaction, shares)

Select another date: